Transforming growth factor beta1 (TGFbeta1) expression in head and neck squamous cell carcinoma patients as related to prognosis
| Autor: | Angela F, Logullo, Suely, Nonogaki, Roberto E, Miguel, Luiz P, Kowalski, Inês N, Nishimoto, Fátima S, Pasini, Miriam H H, Federico, Ricardo R, Brentani, M Mitzi, Brentani |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male Receptor Transforming Growth Factor-beta Type I Protein Serine-Threonine Kinases Transforming Growth Factor beta1 Transforming Growth Factor beta Biomarkers Tumor Humans Laryngeal Neoplasms Aged Aged 80 and over Hypopharyngeal Neoplasms Receptor Transforming Growth Factor-beta Type II Middle Aged Prognosis Immunohistochemistry Gene Expression Regulation Neoplastic Survival Rate Oropharyngeal Neoplasms Head and Neck Neoplasms Case-Control Studies Carcinoma Squamous Cell Female Mouth Neoplasms Activin Receptors Type I Receptors Transforming Growth Factor beta |
| Zdroj: | Journal of oral pathologymedicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 32(3) |
| ISSN: | 0904-2512 |
| Popis: | Transforming growth factor beta1 (TGFbeta1) is a negative growth regulator in keratinocytes, and in vitro studies lead to the concept that loss of TGFbeta1 responsiveness is a critical step in epithelial carcinogenesis.To investigate the prognostic relevance of TGFbeta1 expression in head and neck squamous cell carcinoma (HNSCC).TGFbeta1 distribution was determined by immunohistochemistry in oral cavity/oropharynx (n = 79), larynx (n = 36) and hypopharynx (n = 25) tumors and in matched normal adjacent mucosa. TGFbeta-type I and II receptors were determined in 20 cases of differentiated oral cavity/hypopharynx tumors. Cases were considered positive if displaying reactivity in10% of the cells.TGFbeta1-positive expression was found in 47.2% of larynx, 36.7% of oral cavity/oropharynx and in 24% of the hypopharynx tumors. Reactivity in60% of the cells was displayed only by 11.4% of HNSCC. All normal controls were positive. TGFbeta1-positive expression did not correlate with clinico pathological parameters. An association with differentiation was verified only in oral cavity/oropharynx tumors (P/= 0.001). TGFbeta1 was also not related to 5 years survival (Kaplan-Meier). Strong and diffuse expression of TGFbeta-RII was identified in 19/20 cases regardless of TGFbeta1 immunoreactivity. Out of 17 TGFbeta1-positive oral cavity/oropharynx tumors, only nine expressed TGFbeta-RI suggesting a disruption of the TGFbeta1 pathway. We conclude that TGFbeta1 protein immunostaining is not a useful biomarker in assessment of prognosis in HNSCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text